Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.625
Bid: 0.60
Ask: 0.65
Change: -0.025 (-3.85%)
Spread: 0.05 (8.333%)
Open: 0.65
High: 0.65
Low: 0.625
Prev. Close: 0.65
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Centamin Falls After Gold Production Drops

Mon, 09th Jul 2018 10:08

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------Just Eat, up 2.4%. RBC Capital raised the online takeaway platform to its Top Pick list.BHP Billiton, up 1.8%. Shares in the Anglo-Australian miner were higher after Reuters reported on Friday that oil major BP is in the lead to acquire the US onshore shale oil and gas assets from BHP after submitting an offer over USD10 billion. BP was down 1.0%.----------FTSE 100 - LOSERS----------Hargreaves Lansdown, down 0.9%. JPMorgan downgraded the funds supermarket to Underweight from Neutral. ----------FTSE 250 - WINNERS----------Stobart Group, up 4.8%. The support services firm said on Saturday that its former chief executive had been re-elected and then immediately dismissed. A majority of shareholders, 51%, voted Andrew Tinkler back onto the board at the company's annual general meeting on Friday, the results of which were delayed until Saturday evening. Tinkler's re-election and his subsequent dismissal were announced within Stobart's Saturday AGM results. In its Saturday statement, Stobart noted that Tinkler's election was passed by the required majority but justified its decision to remove him from the board once again. Tinkler stepped down as chief executive last year but remained on the board. He was removed altogether after accusations of "subverting the company for his own interests" and attempting to cash GBP30 million worth of shares, the Daily Mail said.TalkTalk Telecom Group, up 3.5%. JPMorgan raised the home phone and broadband provider to Neutral from Underweight. ----------FTSE 250 - LOSERS----------Centamin, down 7.5%. The gold miner said second quarter gold production from its Sukari mine in Egypt dropped 25% as underground grades fell below forecast. For the three months to June 30, the miner produced 92,803 ounces of gold compared to 124,641 in the comparative year ago period. In the six months to June 30, production fell 7% to 217,099 ounces form 233,828 ounces year-on-year. In May, the company revised its annual production guidance of between 505,000 and 515,000 ounces at a cash cost of production of USD625 to USD640 per ounce produced and an all-in sustaining cost of USD875 to USD890 per ounce sold. "We have experienced several challenges this year, resulting in the revision of our full year guidance in May," said Chief Executive Officer Andrew Pardey.----------OTHER MAIN MARKET AND AIM - WINNERS----------Legendary Investments, up 17%. The investment company recorded double digit growth in investments and net assets in its recently-ended financial year. In the year to the end of March, the company invested GBP6.2 million versus GBP4.3 million the year before. Net assets saw a 28% increase to GBP6.0 million from GBP4.7 million. During the year, one of Legendary's holdings, Virtualstock Holdings received an investment of GBP4.5 million from European venture capital firm Notion Capital. Legendary holds GBP66 million worth of stake in Virtualstock. In addition, Legendary converted its shares in its Kyrgyz gold asset to shares in Circle Oil Tunisia in December 2017, following Circle Oil Tunisia's acquisition by Dunraven Resources, meaning the the company now holds a 2.0% stake in Dunraven.----------OTHER MAIN MARKET AND AIM - LOSERS----------N4 Pharma, down 52%. The drug reformulation company said that its sildenafil reformulation clinical trial has not met its key target endpoints. The company said that the product formulation will need to be reviewed to assess what changed need to be made to make the reformulated drug viable to N4 Pharma's patent position. "This part of the process of drug reformulation is always going to be a challenge and whilst this preliminary data is clearly disappointing, we will need to see the full set of results expected around the end of August to understand the detailed implications for the formulation," said Chief Executive Officer Nigel Theobald.----------
More News
15 Jul 2022 13:23

N4 Pharma upbeat on latest tumour suppression study data

(Sharecast News) - Specialist pharmaceutical developer N4 Pharma updated the market on its recent preclinical study with TNF alpha on Friday.

Read more
15 Jul 2022 11:21

AIM WINNERS & LOSERS: Fevertree lowers guidance; DP Poland sales rise

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
17 Mar 2022 16:28

UK shareholder meetings calendar - next 7 days

Friday 18 March  
Caracal Gold PLCAGM
Chenavari Toro Income Fund LtdAGM
Monday 21 March 
Aferian PLCAGM
Altona Rare Earths PLCAGM
Helical PLCGM re becoming REIT & buyback
Inland Homes PLCAGM
Tuesday 22 March 
Crest Nicholson Holdings PLCAGM
Hochschild Mining PLCEGM re Amarillo Gold acquisition
Hydro Hotel Eastbourne PLCAGM
Starvest PLCAGM
Sureserve Group plcAGM
Wynnstay Group PLCAGM
Wednesday 23 March 
CML Microsystems PLCGM re employee share plans
Quartix Technologies PLCAGM
Strategic Equity Capital PLCGM re: tender offer
Thursday 24 March 
BlackRock Throgmorton Trust PLCAGM
Independent Investment Trust PLCAGM
N4 Pharma PLCAGM
React Group PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
23 Feb 2022 14:54

IN BRIEF: N4 Pharma falls as loss widens and Nuvec tests inconclusive

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company - Reports a pretax loss of GBP1.8 million for 2021, widening 18% from GBP1.6 million the previous year. Says year focused on in vivo studies of Nuvec, a delivery system for cancer treatments and vaccines, which did not return any "meaningful" immunological response in studies carried out by Hamburg-based drug development company Evotec SE. Says that on the back of increased data the company can now narrow its focus on the oncology and gene therapy market.

Read more
31 Jan 2022 22:06

TRADING UPDATES: Hiro plans acquisition vehicle IPO; Aquila reviews

TRADING UPDATES: Hiro plans acquisition vehicle IPO; Aquila reviews

Read more
25 Jan 2022 19:12

TRADING UPDATES: Cordiant raises GBP200 million; Home REIT spends

TRADING UPDATES: Cordiant raises GBP200 million; Home REIT spends

Read more
25 Jan 2022 14:50

N4 Pharma outlines work plan after 'encouraging' data

(Sharecast News) - Specialist treatment and vaccine delivery system developer N4 Pharma updated the market on its work plan on Tuesday, following "encouraging data" from its oncology research as announced on 13 December.

Read more
13 Dec 2021 21:57

IN BRIEF: N4 Pharma to focus resources on gene therapy

IN BRIEF: N4 Pharma to focus resources on gene therapy

Read more
13 Dec 2021 14:56

N4 upbeat on cancer treatment progress, vaccine disappoints

(Sharecast News) - Cancer treatment and vaccine delivery system developer N4 Pharma updated the market on data from its proof-of-concept programmes and ongoing activities on Monday.

Read more
1 Nov 2021 06:57

IN BRIEF: Kings Arms Yard VCT appoints two new non-executive directors

IN BRIEF: Kings Arms Yard VCT appoints two new non-executive directors

Read more
1 Oct 2021 09:35

N4 Pharma granted Europe patent with China equivalent on its way

(Sharecast News) - Specialist pharmaceutical company N4 Pharma announced on Friday that it has been granted a patent for its 'Nuvec' cancer treatment and vaccine delivery system by the European Patent Office (EPO), specifically around its composition, particulate materials, and methods for making the particulate materials.

Read more
1 Oct 2021 08:50

N4 Pharma secures patent in Europe for Nuvec, expects China to follow

N4 Pharma secures patent in Europe for Nuvec, expects China to follow

Read more
20 Sep 2021 12:02

TRADING UPDATES: Christie Group and Open Orphan swing to profit

TRADING UPDATES: Christie Group and Open Orphan swing to profit

Read more
14 Sep 2021 14:31

TRADING UPDATES: Boku launches in Germany; Focusrite trading well

TRADING UPDATES: Boku launches in Germany; Focusrite trading well

Read more
24 Aug 2021 12:35

TRADING UPDATES: IG Design starts year well; Ilika in Stereax progress

TRADING UPDATES: IG Design starts year well; Ilika in Stereax progress

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.